Abstracts

868 – Inflammatory Markers and Frailty, Cognitive Impairment, Clinical Outcomes, and Mortality in PWH

Background The associations among inflammatory markers and prevalent or incident frailty, cognitive impairment (CI), clinical events and all-cause mortality in older people with HIV are poorly understood. Methods Participants from the HAILO study ≥50 years were included. Frailty was evaluated using the Fried Frailty assessment (4-meter walk speed, grip strength, unintentional weight loss, exhaustion, low…

904 – Obstructive Sleep Apnea and Prevalent Diabetes Mellitus in the Multicenter AIDS Cohort Study

Background Obstructive sleep apnea and diabetes are common among people with HIV (PWH). Cardinal features of obstructive sleep apnea such as intermittent hypoxia and sleep fragmentation have been associated with the development of diabetes in the general population. Among PWH, HIV-associated inflammation and the use of certain ART medications have also been associated with the…

896 – Weight Change in Trial of Switching From Second-Line bPI to B/F/TAF in a Context of Food Insecurity

Background Data are limited on weight gain after switching from second-line boosted PI-based regimens to B/F/TAF in low and middle-income countries (LMICs). We assessed weight in a clinical trial that compared continuing boosted PI + NRTIs vs. B/F/TAF during a period of severe civil unrest in Haiti.  Methods The parent study was a prospective, open-label trial…

857 – Acute Drop in eGFR When Initiating SGLT2 Inhibitors vs Other Antihyperglycemic Medications Among PWH

Background Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have demonstrated cardiorenal benefits in the general population but can cause an acute dip in estimated glomerular filtration rate (eGFR), raising safety concerns, particularly in people with HIV (PWH) who may be more vulnerable to renal complications. Due to limited data in PWH, we aimed to assess the risk…

899 – Decreased Adipose Tissue Gene Expression After a 48-Week Switch From an InSTI Regimen to TDF/3TC/DOR

Background INSTIs are known to induce weight/fat gain, the pathogenesis and reversibility of which remain unclear. The ongoing ADDORE study aimed to evaluate the evolution of adipose tissue (AT) between baseline and W48 in PWH with INSTI-associated weight gain switched to TDF/3TC/DOR. We present here preliminary adipocyte gene expression results. Methods PWH underwent two surgical…

863 – Impact of Antidiabetic Medications on Weight Change Among People With HIV

Background While novel antidiabetic medications like glucagon like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose co-transporter 2 inhibitors (SGLT2is) have demonstrated weight loss in the general population, data on their impact on weight loss in PWH remains limited.  Methods We identified adult PWH in the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort who…

905 – Impact of HIV Infection on Adipose Tissue Fibrosis and Its Association With Insulin Resistance

Background People with HIV (PWH) are at elevated risk for type 2 diabetes (T2D), despite viral suppression. While obesity is a well-known driver of T2D in the general population, HIV-specific factors, such as chronic inflammation and antiretroviral therapy (ART), may contribute to risk in PWH. While subcutaneous adipose tissue (SAT) fibrosis promotes insulin resistance in…

900 – In Vitro Modulation of Adipocyte Differentiation by TAF/TDF After Challenge With New ARV Regimens

Background We previously demonstrated in a 3T3L1cells in vitro model of adipogenesis, that Integrase Strand Transfer Inhibitors (INSTI) increase adipogenesis, while, tenofovir alafenamide fumarate (TAF) and tenofovir disoproxil fumarate (TDF), displayed an inhibitory effect, counteracting increased adipogenesis caused by INSTIs [dolutegravir (DTG), bictegravir (BIC)]. Deregulation of the expression levels of two families of adipocyte differentiation transcription factors, the CCAAT/enhancer-binding proteins (C/EBPs) and the…